Compounds > idrapril
Page last updated: 2024-12-06

idrapril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Idrapril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure. It was synthesized in the 1970s and is a prodrug that is converted to its active form in the body. Idrapril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting ACE, idrapril lowers blood pressure by relaxing blood vessels and increasing sodium excretion. Idrapril has been studied for its potential benefits in the treatment of heart failure, kidney disease, and other cardiovascular conditions. Its effectiveness and safety have been established in clinical trials. Idrapril is an important therapeutic agent for managing hypertension and other cardiovascular diseases.'

idrapril: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65960
CHEMBL ID2104330
SCHEMBL ID564220
MeSH IDM0206860

Synonyms (16)

Synonym
(1s,2r)-2-(((hydroxycarbamoyl)methyl)methylcarbamoyl)cyclohexanecarboxylic acid
idrapril [inn]
cyclohexanecarboxylic acid, 2-(((2-(hydroxyamino)-2-oxoethyl)methylamino)carbonyl)-, (1s-cis)-
idrapril
(1s,2r)-2-[[2-(hydroxyamino)-2-oxoethyl]-methylcarbamoyl]cyclohexane-1-carboxylic acid
unii-176p5c4qu8
176p5c4qu8 ,
AKOS015950909
CHEMBL2104330
127420-24-0
idrapril [who-dd]
SCHEMBL564220
DTXSID60155565
Q27251875
cyclohexanecarboxylic acid, 2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]-, (1s,2r)-
(1s,2r)-2-{[(hydroxycarbamoyl)methyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid

Research Excerpts

Overview

Idrapril is a safe and efficient ACE inhibitor in human subjects.

ExcerptReferenceRelevance
"Idrapril is a safe and efficient ACE inhibitor in human subjects."( Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
Brunner, HR; Capone, P; Criscuoli, M; Nussberger, J; Zanchi, A, 1994)		1.25

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic profile and biochemical efficacy of idrapril calcium, a novel angiotensin converting enzyme (ACE) inhibitor, were evaluated in healthy volunteers after multiple dosing for 5 days at the doses of 100, 200 and 400 mg twice daily."( Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
Criscuoli, M; Del Re, G; Grant, J; Lippi, A; Subissi, A; Wyld, PJ, 1994)		0.79

Bioavailability

ExcerptReferenceRelevance
" It is well absorbed orally."( Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
Brunner, HR; Capone, P; Criscuoli, M; Nussberger, J; Zanchi, A, 1994)		0.52
" Absolute oral bioavailability was calculated to be approximately 24% in rats and dogs."( Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
Criscuoli, M; Giachetti, A; Lippi, A; Mengozzi, G; Sardelli, G; Subissi, A, )		0.4

Dosage Studied

ExcerptRelevanceReference
"The pharmacokinetic profile and biochemical efficacy of idrapril calcium, a novel angiotensin converting enzyme (ACE) inhibitor, were evaluated in healthy volunteers after multiple dosing for 5 days at the doses of 100, 200 and 400 mg twice daily."( Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
Criscuoli, M; Del Re, G; Grant, J; Lippi, A; Subissi, A; Wyld, PJ, 1994)		0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.45 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (35.71%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (64.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
substance p
[no description available]		1.9810peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		9.2941alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		4.3322amino acid zwitterion;
angiotensin II		human metabolite
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		1.9810capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		1.9810dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		1.9810dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
angiotensin i
Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.		1.9810angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		04.0631
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		04.0631
Injury, Myocardial Reperfusion
[description not available]		01.9910
Heart Disease, Ischemic
[description not available]		01.9910
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		01.9910
Left Ventricular Dysfunction
[description not available]		06.9910
Cardiovascular Stroke
[description not available]		01.9910
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		06.9910
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		01.9910